JILIN AODONG(SZ:000623)2024-03-07 08:37Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. has a history of over 40 years and is known for its core product, "Anshen Bnnao Liquid," which has maintained strong market vitality [2][3]. - The company reported annual sales revenue exceeding 600 million CNY for "Anshen Bnnao Liquid," highlighting its significant market presence [3]. Group 2: Product Development and R&D - The company is actively advancing R&D projects focused on new products and secondary development of major varieties, including traditional Chinese medicine and chemical drugs [4]. - It has obtained multiple approvals for new drug formulations, including 1 approval for a traditional Chinese medicine and 2 approvals for chemical drugs [4]. Group 3: Investment in Guangfa Securities - Since 1999, the company has invested in Guangfa Securities, becoming the largest shareholder in 2016, and has increased its stake over the years [4]. - As of January 20, 2024, the company holds 1,252,768,767 A-shares (16.44% of total shares) and 236,666,600 H-shares (3.11% of total shares) in Guangfa Securities, with a total market value of approximately 20 billion CNY [4][5]. Group 4: Future Development Plans - The company aims to focus on "people and medicine," integrating resources and increasing R&D investment to drive high-quality development in the pharmaceutical industry [5]. - Plans include expanding sales channels for "Anshen Bnnao Liquid" and "Xiaoer Chaigui Reqing Oral Liquid," while also enhancing market management for injectable drugs [5].